Assessment of Finite and Infinite Dose In Vitro Experiments in Transdermal Drug Delivery.

in silico in vitro penetration/finite doses permeation/infinite doses porcine skin

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
10 Mar 2021
Historique:
received: 07 01 2021
revised: 19 02 2021
accepted: 06 03 2021
entrez: 3 4 2021
pubmed: 4 4 2021
medline: 4 4 2021
Statut: epublish

Résumé

Penetration, usually with finite dosing, provides data about the total active amount in the skin and permeation, being the most used methodology, usually with infinite dosing, leads to data about pharmacokinetic parameters. The main objective of this work is to assess if results from permeation, most of them at finite dose, may be equivalent to those from penetration usually at infinite dose. The transdermal behavior of four drugs with different physicochemical properties (diclofenac sodium, ibuprofen, lidocaine, and caffeine) was studied using penetration/finite and kinetic permeation/infinite dose systems using vertical Franz diffusion cells to determine the relationships between permeation and penetration profiles. Good correlation of these two in vitro assays is difficult to find; the influence of their dosage and the proportion of different ionized/unionized compounds due to the pH of the skin layers was demonstrated. Finite and infinite dose regimens have different applications in transdermal delivery. Each approach presents its own advantages and challenges. Pharmaceutical industries are not always clear about the method and the dose to use to determine transdermal drug delivery. Being aware that this study presents results for four actives with different physicochemical properties, it can be concluded that the permeation/infinite results could not be always extrapolated to those of penetration/finite. Differences in hydrophilicity and ionization of drugs can significantly influence the lack of equivalence between the two methodologies. Further investigations in this field are still needed to study the correlation of the two methodologies and the main properties of the drugs that should be taken into account.

Identifiants

pubmed: 33801998
pii: pharmaceutics13030364
doi: 10.3390/pharmaceutics13030364
pmc: PMC8000447
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Br J Dermatol. 2009 Jan;160(1):80-91
pubmed: 18811683
J Pharmacobiodyn. 1988 Sep;11(9):636-44
pubmed: 3216285
Fundam Appl Toxicol. 1993 Aug;21(2):213-21
pubmed: 8405784
J Pharm Sci. 2008 Jan;97(1):584-98
pubmed: 17722002
Pharm Res. 1992 May;9(5):663-9
pubmed: 1608900
Pharm Res. 2010 Jan;27(1):134-42
pubmed: 19904581
Int J Cosmet Sci. 2012 Dec;34(6):525-35
pubmed: 22950455
Adv Drug Deliv Rev. 2007 Sep 30;59(11):1152-61
pubmed: 17889400
J Invest Dermatol. 1975 Jul;65(1):71-84
pubmed: 1097542
Pharmaceutics. 2019 Jul 02;11(7):
pubmed: 31269690
Skin Pharmacol Physiol. 2006;19(6):296-302
pubmed: 16864974
Curr Med Chem. 2012;19(27):4671-7
pubmed: 22934776
Regul Toxicol Pharmacol. 2010 Jul-Aug;57(2-3):200-9
pubmed: 20178823
J Pharm Sci. 2008 Apr;97(4):1578-92
pubmed: 17722104
Eur J Pharm Sci. 2019 Aug 1;136:104945
pubmed: 31163216
Int J Mol Sci. 2019 Jun 28;20(13):
pubmed: 31261723
J Control Release. 2001 Aug 10;75(3):283-95
pubmed: 11489316
Int J Pharm. 2019 Feb 10;556:142-149
pubmed: 30529662
Pharmaceutics. 2020 Feb 13;12(2):
pubmed: 32070011
Int J Pharm. 2020 Mar 30;578:119186
pubmed: 32112931
Br J Dermatol. 2018 Nov;179(5):1049-1055
pubmed: 30022486
Adv Drug Deliv Rev. 2013 Feb;65(2):278-94
pubmed: 22750806
Chem Pharm Bull (Tokyo). 1992 Nov;40(11):3090-3
pubmed: 1477925
Toxicol In Vitro. 2002 Jun;16(3):299-317
pubmed: 12020604
Drug Test Anal. 2018 Oct;10(10):1528-1535
pubmed: 29788546
Pharm Res. 1990 Mar;7(3):230-6
pubmed: 2339094
Int J Pharm. 2011 Apr 15;408(1-2):223-34
pubmed: 21316430
Oman Med J. 2010 Jul;25(3):155-1661
pubmed: 22043330
Anesth Prog. 2006 Fall;53(3):98-108; quiz 109-10
pubmed: 17175824
J Pharm Sci. 2007 Mar;96(3):682-703
pubmed: 17080423
Pharm Res. 2017 Aug;34(8):1728-1740
pubmed: 28540502
Toxicol Sci. 1998 Sep;45(1):42-51
pubmed: 9848109
Pharm Res. 1989 Nov;6(11):931-7
pubmed: 2594684

Auteurs

Luisa Coderch (L)

Surfactants and Nanobiotechnology Department, IQAC-CSIC, Jordi Girona 18-26, 08034 Barcelona, Spain.

Ilaria Collini (I)

Surfactants and Nanobiotechnology Department, IQAC-CSIC, Jordi Girona 18-26, 08034 Barcelona, Spain.

Victor Carrer (V)

Surfactants and Nanobiotechnology Department, IQAC-CSIC, Jordi Girona 18-26, 08034 Barcelona, Spain.

Clara Barba (C)

Surfactants and Nanobiotechnology Department, IQAC-CSIC, Jordi Girona 18-26, 08034 Barcelona, Spain.

Cristina Alonso (C)

Surfactants and Nanobiotechnology Department, IQAC-CSIC, Jordi Girona 18-26, 08034 Barcelona, Spain.

Classifications MeSH